| Bioactivity | Troriluzole, a third-generation, tripeptide prodrug of Riluzole (HY-B0211), is an orally active glutamate modulator. Troriluzole reduces synaptic glutamate level and increases the synaptic glutamate absorption. Troriluzole has the potential for Alzheimer disease and generalized anxiety disorder (GAD)[1][2]. | ||||||||||||
| Target | glutamate | ||||||||||||
| Invitro | Troriluzole is absorbed systemically and cleaves into riluzole by aminopeptidases[1]. | ||||||||||||
| Name | Troriluzole | ||||||||||||
| CAS | 1926203-09-9 | ||||||||||||
| Formula | C15H16F3N5O4S | ||||||||||||
| Molar Mass | 419.38 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Schanzer B, et al. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov;28(11):1003-1012. [2]. Huang LK, et al. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020 Jan 6;27(1):18. |
Troriluzole
CAS: 1926203-09-9 F: C15H16F3N5O4S W: 419.38
Troriluzole, a third-generation, tripeptide prodrug of Riluzole (HY-B0211), is an orally active glutamate modulator. Tro
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.